3 juni 2026: Bron ASCO 2026

Uit de fase III studie EMERALD-3 blijkt dat toevoeging van de immuuntherapeutische combinatiebehandeling met Tremelimumab (merknaam Imjudo) en Durvalumab (merknaam STRIDE) aan Transarteriële chemo-embolisatie (TACE), met of zonder lenvatinib, bij patiënten met primaire leverkanker (HCC) betere ziekteprogressievrije tijd geeft en een betere overall overleving op 2-jaars meting in vergelijking met alleen TACE.

Belangrijkste bevindingen:

In de Durvalumab (merknaam STRIDE),  lenvatinib- en TACE-groep was de mediane ziekteprogressievrije overleving 13 maanden, vergeleken met 9,8 maanden in de groep die alleen TACE kreeg.
De Durvalumab-,lenvatinib- en TACE-groep had een mediane algehele overleving (OS) van 39,5 maanden, vergeleken met 34,7 maandenin de groep die alleen TACE kreeg..
De 2-jaars OS-kans in de groep met de drievoudige combinatie was 66,9%, vergeleken met 61,5% in de groep die alleen TACE kreeg.
Bij vergelijking van de 175 deelnemers die Durvalumab en TACE zonder  lenvatinib kregen met de eerste 175 deelnemers die alleen TACE kregen, bleek dat de groep die Durvalumab en TACE kreeg nog steeds een langere ziekteprogressievrije overleving  had (respectievelijk 12,9 maanden versus 8,1 maanden).

De 2-jaars OS-kans was in deze groep ook hoger (respectievelijk 68% versus 57,8%).

Het abstract is te lezen op ASCO 2026:

Jun 1, 2026
ASCO Perspective Quote
“The significant improvement in progression-free survival observed in the phase 3 EMERALD-3 study positions this combinatorial regimen of single tremelimumab regular interval durvalumab (STRIDE) plus transarterial chemoembolization (TACE), with or without lenvatinib, as a compelling therapeutic option for patients with unresectable embolization-eligible hepatocellular carcinoma. These findings are likely to influence clinical practice and may be considered practice-changing for medical oncologists treating hepatocellular carcinoma globally,” said ASCO Expert Vishwanath Sathyanarayanan, MD, DM, Lead Oncosciences, Karnataka Region, Apollo Hospitals, Bangalore, India.
 
Study at a Glance
 
Focus Embolization-eligible unresectable hepatocellular carcinoma (eeHCC)
Population 760 participants
Main Takeaway Combining single tremelimumab regular interval durvalumab (STRIDE) with transarterial chemoembolization (TACE), with or without lenvatinib, can slow cancer growth for people with embolization-eligible unresectable hepatocellular carcinoma that cannot be removed with surgery, and it may help them live longer.
Significance
  • In 2026, the American Cancer Society (ACS) estimates that 42,340 people in the United States (U.S.) will be diagnosed with liver cancer, and 30,980 people will die from the disease. Over the past 4 decades, liver cancer diagnoses in the U.S. have tripled. 
  • The most common type of liver cancer is called hepatocellular carcinoma (HCC), which accounts for more than 8 in 10 liver cancer diagnoses. HCC is commonly diagnosed at later stages, when surgery is not an option.
  • At later stages of disease, about 30% of patients are eligible for treatment with TACE. For more than 2 decades, this has been the standard of care for people with eeHCC that cannot be removed with surgery. However, cancer often grows or spreads in patients within 8 to 10 months of receiving this treatment.
 
ALEXANDRIA, Va.—Results from the Phase 3 EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s growth and may help patients with embolization-eligible hepatocellular carcinoma that cannot be removed with surgery live longer. The research will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. 
 
About the Study 
“In the embolization-eligible setting for hepatocellular carcinoma, transarterial chemoembolization has been the most practiced global standard of care for over 2 decades. However, outcomes remain poor, with a median progression-free survival of 8 to 10 months. Repeated TACE procedures wane in effect over time and risk further decline in liver function. Currently there are no systemic therapy-based options approved for these patients globally,” said lead study author Ghassan K. Abou-Alfa, MD, PhD, MBA, JD, FASCO.
 
The global EMERALD-3 trial tested whether combining STRIDE with TACE⁠, either with or without adding the oral targeted therapy drug lenvatinib, could delay cancer growth for people with embolization-eligible unresectable hepatocellular carcinoma that could not be removed with surgery, when compared to TACE alone. The study included 760 participants, all of whom were at least 18 years old, or over 21 for those living in Egypt or Singapore. Participants were predominantly male (83.2%) and Asian (72.1%).
 
Participants were randomly assigned to receive either STRIDE and lenvatinib with TACE (293 participants), STRIDE with TACE (175 participants), or TACE alone (292 participants).
 
Key Findings
  • In the STRIDE, Lenvatinib, and TACE group, the median progression-free survival (PFS) was 13 months vs. 9.8 months in the TACE-alone group. 
  • The STRIDE, lenvatinib, and TACE group had a median overall survival (OS) of 39.5 months vs. 34.7 months in the TACE-alone group.
  • The 2-year OS rate in the triple-combination group was 66.9% vs. 61.5% in the TACE-alone group.
  • When looking at the 175 participants who received STRIDE and TACE without lenvatinib compared to the first 175 participants who received TACE alone, those who received STRIDE and TACE still had a longer PFS (12.9 months vs. 8.1 months, respectively). The 2-year OS rate was also higher in this group (68% vs. 57.8%, respectively).
Those who received STRIDE and TACE with or without lenvatinib experienced more side effects than those who received TACE alone. The rate of grade 3 or 4 adverse events, which represent severe or life-threatening side effects, was 62.7% in those who received STRIDE with lenvatinib and TACE, 48.6% for those who received STRIDE with TACE, and 18.6% for those who received TACE alone. The most common side effects in each group were consistent with the known side effects for each treatment.
 
Next Steps 
The EMERALD-3 study is ongoing, and patients are being followed for OS final analyses.
 
The EMERALD-3 study was funded by AstraZeneca.
 
 
 


ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

Primaire leverkanker, Immuuntherapie, Tremelimumab, Durvalumab, Stride, Lenvatinib, Transarteriële chemo-embolisatie, TACE, ziekteprogressievrije overleving, overall overleving


Plaats een reactie ...

Reageer op "Tremelimumab plus durvalumab al of niet in combinatie met lenvatinib aanvullend op transarteriële chemo-embolisatie (TACE) geeft betere overleving bij primaire leverkanker in vergelijking met alleen TACE"


Gerelateerde artikelen
 

Gerelateerde artikelen

Tremelimumab plus durvalumab >> Camrelizumab plus Rivoceranib >> Immuuntherapie met Atezolizumab >> Immuuntherapie: voedingspatroon, >> Immuuntherapie met anti-PD >>